IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $3,537.42 today based on a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...